Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker TENX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Phillip Gross | 857,270 | 2.3% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Robert Atchinson | 857,270 | 2.3% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Adage Capital Management, L.P. | 857,270 | 2.3% | SCHEDULE 13G/A ↗ |
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BlackRock, Inc. | 2.80M | 7.5% | SCHEDULE 13G/A ↗ |
| Oct 15, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Israel A. Englander | 1.36M | 3.6% | SCHEDULE 13G/A ↗ |
| Oct 15, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Millennium Group Management LLC | 1.36M | 3.6% | SCHEDULE 13G/A ↗ |
| Oct 15, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Millennium Management LLC | 1.36M | 3.6% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Sphera Global Healthcare Management LP | 2.66M | 7.1% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Sphera Global Healthcare GP Ltd. | 2.66M | 7.1% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Sphera Funds Management Ltd. | 2.66M | 7.1% | SCHEDULE 13G/A ↗ |
| Oct 9, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Kevin Pyun | 2.40M | 6.4% | SCHEDULE 13G/A ↗ |
| Oct 9, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Dellora Investments LP | 2.40M | 6.4% | SCHEDULE 13G/A ↗ |
| Oct 9, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Dellora Investments Master Fund LP | 2.06M | 5.5% | SCHEDULE 13G/A ↗ |
| Sep 11, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | ING Capital Markets LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Sep 11, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | ING Groep N.V. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Sep 8, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Daniel Schneeberger | 5.26M | 14.0% | SCHEDULE 13G ↗ |
| Sep 8, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | ADAR1 Capital Management, LLC | 5.26M | 14.0% | SCHEDULE 13G ↗ |
| Sep 8, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Abigail P. Johnson | 514,925 | 1.4% | SCHEDULE 13G/A ↗ |
| Sep 8, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | FMR LLC | 514,925 | 1.4% | SCHEDULE 13G/A ↗ |
| Aug 27, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Sphera Global Healthcare Management LP | 1.99M | 5.3% | SCHEDULE 13G ↗ |
| Aug 27, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Sphera Global Healthcare GP Ltd. | 1.99M | 5.3% | SCHEDULE 13G ↗ |
| Aug 27, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Sphera Funds Management Ltd. | 1.99M | 5.3% | SCHEDULE 13G ↗ |
| Aug 27, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | ING Capital Markets LLC | 2.64M | 7.0% | SCHEDULE 13G ↗ |
| Aug 27, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | ING Groep N.V. | 2.64M | 7.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Israel A. Englander | 2.16M | 5.8% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Millennium Group Management LLC | 2.16M | 5.8% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | TENX Tenax Therapeutics, Inc. | Millennium Management LLC | 2.16M | 5.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Roderick Wong | 2.87M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | RTW Investments, LP | 2.87M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Bong Y. Koh | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Nimish Shah | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | VHCP Management EG, LLC | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | VHCP Management III, LLC | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 1.57M | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Vivo Opportunity, LLC | 3.46M | 9.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Vivo Opportunity Fund Holdings, L.P. | 3.46M | 9.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Neil Shahrestani | 1.08M | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Ikarian Capital, LLC | 1.08M | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 1.70M | 4.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Joseph Edelman | 1.70M | 4.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Perceptive Advisors LLC | 1.70M | 4.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Mark N. Lampert | 3.11M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BVF Inc/Il | 3.11M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BVF Partners L P/Il | 3.11M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BVF GP Holdings LLC | 3.11M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BVF Partners OS Ltd. | 7 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP | 7 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TENX Tenax Therapeutics, Inc. | BVF II GP LLC | 141,570 | 0.5% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances